ZAI LAB ALERT: Bragar Eagel & Squire, P.C. is Investigating Zai Lab Limited on Behalf of Zai Lab Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB) on behalf of Zai Lab stockholders.
- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB) on behalf of Zai Lab stockholders.
- Our investigation concerns whether Zai Lab has violated the federal securities laws and/or engaged in other unlawful business practices.
- Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them.
- On June 6, 2023, Zai Lab reported phase 3 trials for an oncology therapy it is developing with NovoCure.